Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer

Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Cancer Research at the University of Alberta.

Nanostics Inc., a precision health diagnostics company, is excited to launch a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, ClarityDX Bladder, using its ClarityDX® diagnostic platform. In partnership with the University of Alberta’s Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs, the study will recruit patients at sites in Alberta and Northern Ontario. Financial support for the study is provided with a $600,000 financial contribution through the Alberta Innovates AICE-Concepts Program. A preliminary 142-patient study with ClarityDX Bladder showed that it could accurately identify patients with bladder cancer compared to healthy individuals.

Recommended AI News: Pecan AI Announces One-Click Data Science Model Deployment

Bladder cancer is the fifth most prevalent cancer in North America. Seventy percent of bladder cancer cases are low-grade, noninvasive, non-fatal, recurring tumors requiring life-long surveillance. The remaining 30% are high-grade, aggressive, fatal tumors requiring rapid and intensive treatment. Most bladder cancers are asymptomatic, making diagnosis and follow-up surveillance a significant challenge. Currently, bladder cancers are diagnosed using cystoscopy, the gold standard procedure for bladder cancer screening, and monitored with urine cytology tests. Cystoscopy is invasive, uncomfortable, and has limited detection capacity for some forms of bladder cancer.

Nanostics’ ClarityDX Bladder test uses extracellular vesicle detection technology and machine-learning model analysis to identify the most potent disease predictors for the early detection of bladder cancer.

Related Posts
1 of 30,731

“Strategic investments in digital health are enabling Alberta to become more globally competitive towards increasing health and economic benefits for our province,” says Sunil Rajput, Director of Research for Health Innovation with Alberta Innovates. “Our AICE-Concepts Program is a strong example of digital health investments to power research towards addressing unmet clinical needs.”

Recommended AI News: Waymark Launches Scalable Machine Learning Platform to Accelerate Video Creation for TV and OTT

Implementing ClarityDX Bladder as a highly accurate, noninvasive bladder cancer test will allow for straightforward diagnosis of low-grade bladder cancers and more rapid detection of aggressive bladder cancer before cystoscopy. This would transform bladder cancer care by making it easier to detect changes in tumor status without cystoscopy and improving active surveillance of bladder cancer patients.

“We are excited to launch our bladder cancer study and thank all the patients for their generous participation in the study,” John Lewis, CEO of Nanostics said, “the detection of early-stage bladder cancer is a critical first step for improving patient outcomes.”

Recently, Nanostics announced positive results from the clinical validation study of its lead prostate cancer diagnostic test, ClarityDX Prostate®, showing 94% sensitivity, 37% specificity, 49% positive predictive value, and 90% negative predictive value for predicting clinically significant (grade group ≥2) prostate cancer. Implementation could eliminate up to 37% of unnecessary biopsies and significantly reduce the number of unnecessary treatments for prostate cancer.

Recommended AI News: Avertium Fusion MXDR for Microsoft Security

[To share your insights with us, please write to]

Comments are closed.